

HETEROCYCLES, Vol. 96, No. 4, 2018, pp. 757 - 765. © 2018 The Japan Institute of Heterocyclic Chemistry
Received, 20th February, 2018, Accepted, 9th March, 2018, Published online, 13th March, 2018
DOI: 10.3987/COM-18-13879

A FACILE SYNTHESIS OF 1,4-DIHYDRO-2*H*-PYRIMIDO[4,5-*d*][1,3]OXAZIN-2-ONE DERIVATIVES FROM 4,6-DICHLORO-2-(METHYLSULFANYL)PYRIMIDINE

Kazuhiro Kobayashi,^{a*} Yuka Tsunomori,^a Takashi Nogi,^a Hidetaka Hiyoshi,^b and Kazuto Umezu^c


^a Applied Chemistry Field, Chemistry and Biotechnology Course, Department of Engineering, Graduate School of Sustainability Science, Tottori University, 4-101 Koyama-minami, Tottori 680-8552, Japan. E-mail: kkoba@chem.tottori-u.ac.jp

^b Process Chemistry Development Section, Research & Development Planning Department, Research & Development Division, KUMIAI CHEMICAL INDUSTRY CO., LTD., 4-26 Ikenohata 1-chome, Taito-ku, Tokyo 110-8782, Japan. ^c Process Chemistry Research Center, Chemical Research Institute, Research & Development Division, KUMIAI CHEMICAL INDUSTRY CO., LTD., 2256 Nakanogo, Fuji, Shizuoka 421-3306, Japan. E-mail: kazuto.umezu@kumiai-chem.co.jp

Abstract – A facile three-step sequence has been developed for the preparation of 1,4-dihydro-2*H*-pyrimido[4,5-*d*][1,3]oxazin-2-one derivatives from 4,6-dichloro-2-(methylsulfanyl)pyrimidine (DCSMP) under mild conditions. Thus, the starting material is treated with LDA to generate the 5-lithiated compound, which is then allowed to react with (het)aromatic and aliphatic aldehydes to give the corresponding 1-[4,6-dichloro-2-(methylsulfanyl)pyrimidin-5-yl]alkan-1-ols. The reaction of these compounds with primary amines in the presence of triethylamine gives 1-[4-(alkylamino)-6-chloro-2-(methylsulfanyl)pyrimidin-5-yl]alkan-1-ols, of which subjection to successive treatment with an equimolar amount each of sodium hydride and ethyl chloroformate provides the desired 1,4-disubstituted 7-(methylsulfanyl)-1,4-dihydro-2*H*-pyrimido[4,5-*d*][1,3]oxazin-2-ones.

Compounds with the 1,4-dihydro-2*H*-pyrimido[4,5-*d*][1,3]oxazin-2-one structure are known to exhibit a variety of biological activities,¹ such as calcitonin gene-related peptide (CGDR) receptor antagonistic,^{1a} mutant isocitrate dehydrogenase 1 (IDH1) inhibitory,^{1e} and epidermal growth factor receptor (EGFR) L858R/T790M inhibitory activities.^{1g} Previous synthesis of 1,4-dihydro-2*H*-pyrimido[4,5-*d*][1,3]oxazin-2-one derivatives involves carbonylation of 1-(4-aminopyrimidin-5-yl)alkanols, derived from 4-aminopyrimidine-5-carboxylic acid derivatives, with di(imidazol-1-yl)methanone.¹ However, this method is of limited general applicability. Recently, 4,6-dichloro-2-(methylsulfanyl)pyrimidine (DCSMP) (**1**) has been shown to be a versatile starting materials for the preparation of pyrimidine-fused heterocyclic compounds by us.² Subsequently, we herein wish to describe the results of our study on exploration of a further utilization of this pyrimidine derivative, which offer a general, mild, and efficient approach to 1,4-dihydro-2*H*-pyrimido[4,5-*d*][1,3]oxazin-2-one derivatives (**4**).

Our three-step synthesis of 1,4-disubstituted 7-(methylsulfanyl)-1,4-dihydro-2*H*-pyrimido[4,5-*d*][1,3]oxazin-2-ones (**4**) from DCSMP (**1**) was conducted according to the sequence illustrated in Scheme 1. Compound (**1**) was converted into 1-[4,6-dichloro-2-(methylsulfanyl)pyrimidin-5-yl]alkan-1-ols (**2**) by the treatment with LDA in THF at $-78\text{ }^{\circ}\text{C}$, followed by reaction of the resulting 5-lithio derivative with various aldehydes, as reported in the previous paper.^{2f} Displacement of one of the two chloro substituents of **2** with primary amines in the presence of triethylamine in DMF at $0\text{ }^{\circ}\text{C}$ proceeded smoothly and cleanly to give the corresponding 1-[4-(alkylamino)-6-chloro-2-(methylsulfanyl)pyrimidin-5-yl]alkan-1-ols (**3**) in excellent yields as listed in Table 1.



Scheme 1

Initially, after treatment of compounds (**3**) with two molar equivalents of sodium hydride in DMF or THF at $0\text{ }^{\circ}\text{C}$, the resulting reaction mixtures were treated with an equimolar amount of ethyl chloroformate at the same temperature. The reactions resulted in the immediate formation of rather complicated mixtures of products, from which only about 30% yields of the desired products (**4**) were isolated. Reactions of **3**


with an equimolar amount each of sodium hydride and ethyl chloroformate in THF at 0 °C were then examined and we were pleased to find that the oxazinone ring formation proceeded smoothly and relatively cleanly under these conditions to afford, after usual aqueous workup and subsequent purification by column chromatography on silica gel, the desired products (**4**). The results are also summarized in Table 1, which shows that the products were obtained in moderate to fair yields.

Table 1. Preparation of 3,4-dihydro-2*H*-pyrimido[4,5-*d*][1,3]oxazin-2-ones (**4**)

Entry	2	R' in R'NH ₂	3	Yield/% ^a	4	Yield/% ^a
1	2a (R = Ph)	Me	3a	93	4a	75
2	2a	Et	3b	88	4b	71
3	2a	Bn	3c	94	4c	70
4	2b (R = 4-ClC ₆ H ₄)	Me	3d	87	4d	76
5	2b	<i>n</i> -Bu	3e	90	4e	72
6	2c (R = 4-MeOC ₆ H ₄)	Me	3f	70	4f	73
7	2c	Ph(CH ₂) ₂	3g	88	4g	68
8	2d (R = thiophen-3-yl)	Me	3h	89	4h	67
9	2e (R = Et)	Me	3i	88	4i	76
10	2f (R = <i>i</i> -Pr)	Me	3j	95	4j	59

^a Yields of isolated products.

It is presumed that the deprotonation of the hydroxy hydrogen of **3** with sodium hydride generates the corresponding sodium alkoxides. These are then ethoxycarbonylated with ethyl chloroformate to give the intermediate ethyl carbonates (**5**), which cyclize to the desired cyclic urethanes (**4**). The reactions using phenyl chloroformate or dimethyl carbonate in place of ethyl chloroformate under similar conditions were attempted. However, these gave somewhat decreased yields of the desired products. As can be seen from Entries 1-7, the sizes of the R' substituents slightly affected the reactivity of **3**. The yields of the products decreased, according as the substituents were bulkier. A similar steric effect was observed with regard to the R substituents; the yield of the product (**4j**) from (**3j**) (R = *i*-Pr, Entry 10) was rather lower than those of **4a**, **4d**, **4f**, **4h**, and **4i**.



Scheme 2

In conclusion, a new three-step sequence starting from commercially available 4,6-dichloro-2-(methylsulfanyl)pyrimidine (DCSMP) (**1**) has been shown to provide an efficient approach to 1,4-dihydro-2*H*-pyrimido[4,5-*d*][1,3]oxazin-2-one derivatives (**4**). Notable advantages of the present synthesis include the simplicity of the procedure, the mild reaction conditions, and the ready availability of the starting materials. We are currently investigating the use of this pyrimidine derivative to prepare other important pyrimidine-fused heterocycles.

EXPERIMENTAL

All melting points were obtained on a Laboratory Devices MEL-TEMP II melting apparatus and are uncorrected. IR spectra were recorded with a Perkin–Elmer Spectrum 65 FTIR spectrophotometer. ¹H NMR and ¹³C NMR spectra were recorded using TMS as an internal reference with a JEOL ECP500 FT NMR spectrometer operating at 500 and 125 MHz, respectively. High-resolution MS spectra were measured by a Thermo Scientific Exactive spectrometer (ESI, positive) or a JEOL JMS-T100GCV (EI, TOF; 70eV) spectrometer. Elemental analyses were performed with an Elementar Vario EL II instrument. TLC was carried out on Merck Kieselgel 60 PF₂₅₄. Column chromatography was performed using WAKO GEL C-200E. All of the organic solvents used in this study were dried over appropriate drying agents and distilled prior to use.

Starting Materials. 1-[4,6-Dichloro-2-(methylsulfanyl)pyrimidin-5-yl]alkan-1-ols (**2**) were prepared according to the reported method.^{2f} *n*-BuLi was supplied by Asia Lithium Corporation. All other chemicals used in this study were commercially available.

Typical Procedure for the Preparation of 1-(Pyrimidin-5-yl)alkanols (3). [4-Chloro-6-(methylamino)-2-(methylsulfanyl)pyrimidin-5-yl]phenylmethanol (**3a**). To a stirred solution of **2a** (0.22 g, 0.73 mmol) in DMF (2 mL) containing Et₃N (74 mg) at 0 °C was added MeNH₂ (40% in H₂O; 0.73 mmol) dropwise. After 30 min, H₂O (30 mL) was added and the mixture was extracted with AcOEt (3 × 10 mL). The combined extracts were washed with H₂O (3 × 15 mL) and brine (10 mL), dried (Na₂SO₄), and concentrated by evaporation. The residual solid was recrystallized from CH₂Cl₂ to give **3a** (0.20 g, 93%); a white solid; mp 180–182 °C; IR (KBr) 3393, 3181, 1568 cm⁻¹; ¹H NMR (CDCl₃) δ 2.51 (s, 3H), 2.89 (d, *J* = 4.6 Hz, 3H), 3.75 (br s, 1H), 6.38 (s, 1H), 6.54 (q, *J* = 4.6 Hz, 1H), 7.26–7.39 (m, 5H); ¹³C NMR (CDCl₃) δ 14.1, 28.1, 70.6, 110.0, 125.5, 127.8, 128.5, 139.5, 153.7, 161.2, 170.5. Anal. Calcd for C₁₃H₁₄ClN₃OS: C, 52.79; H, 4.77; N, 14.21. Found: C, 52.68; H, 4.82; N, 14.03.

[4-Chloro-6-(ethylamino)-2-(methylsulfanyl)pyrimidin-5-yl]phenylmethanol (**3b**): a pale-yellow solid; mp 169–171 °C (hexane/THF); IR (KBr) 3391, 3315, 1570 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 0.98 (t, *J* = 7.4 Hz, 3H), 2.44 (s, 3H), 3.29–3.36 (m, 2H), 6.14 (d, *J* = 3.8 Hz, 1H), 6.79 (d, *J* = 3.8 Hz, 1H), 7.13 (t, *J* = 6.4 Hz, 1H), 7.25 (t, *J* = 6.9 Hz, 1H), 7.32 (dd, *J* = 7.6, 6.9 Hz, 2H), 7.37 (d, *J* = 7.6 Hz, 2H); ¹³C NMR

(DMSO-*d*₆) δ 13.4, 14.2, 35.4, 69.2, 110.9, 125.3, 127.3, 128.2, 141.2, 154.5, 160.2, 168.8. Anal. Calcd for C₁₄H₁₆ClN₃OS: C, 54.28; H, 5.21; N, 13.56. Found: C, 54.21; H, 5.32; N, 13.60.

{4-Chloro-2-(methylsulfanyl)-6-[(phenylmethyl)amino]pyrimidin-5-yl}phenylmethanol (3c): a white solid; mp 189–191 °C (CHCl₃); IR (KBr) 3350, 3204, 1571 cm⁻¹; ¹H NMR (CDCl₃) δ 2.42 (s, 3H), 3.52 (br s, 1H), 4.46 (dd, *J* = 15.5, 5.2 Hz, 1H), 4.68 (dd, *J* = 15.5, 6.3 Hz, 1H), 6.43 (s, 1H), 6.79 (dd, *J* = 6.3, 5.2 Hz, 1H), 6.93–6.94 (m, 2H), 7.18–7.20 (m, 3H), 7.29–7.35 (m, 3H), 7.39 (d, *J* = 7.4 Hz, 2H); ¹³C NMR (CDCl₃) δ 14.1, 44.8, 70.4, 110.3, 125.5, 127.0, 127.1, 127.8, 128.4, 128.5, 138.2, 139.6, 156.0, 160.0, 170.6. HR-MS (EI). Calcd for C₁₉H₁₈ClN₃OS (M): 371.0859. Found: *m/z* 371.0853.

[4-Chloro-6-(methylamino)-2-(methylsulfanyl)pyrimidin-5-yl](4-chlorophenyl)methanol (3d): a white solid; mp 179–181 °C (hexane/CH₂Cl₂); IR (KBr) 3409, 3218, 1575 cm⁻¹; ¹H NMR (CDCl₃) δ 2.51 (s, 3H), 2.90 (d, *J* = 4.6 Hz, 3H), 3.98 (br s, 1H), 6.34 (s, 1H), 6.50 (q, *J* = 4.6 Hz, 1H), 7.31 (s, 4H); ¹³C NMR (CDCl₃) δ 14.1, 28.1, 70.0, 109.6, 127.0, 128.6, 133.6, 138.0, 155.6, 161.1, 170.7. Anal. Calcd for C₁₃H₁₃Cl₂N₃OS: C, 47.28; H, 3.97; N, 12.72. Found: C, 47.23; H, 3.99; N, 12.76.

[4-(Butylamino)-6-chloro-2-(methylsulfanyl)pyrimidin-5-yl](4-chlorophenyl)methanol (3e): a white solid; mp 152–154 °C (hexane/CH₂Cl₂); IR (KBr) 3380, 3193, 1575 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 0.75 (t, *J* = 7.6 Hz, 3H), 1.03 (sext, *J* = 7.6 Hz, 2H), 1.33 (quint, *J* = 7.6 Hz, 2H), 2.40 (s, 3H), 3.23–3.28 (m, 1H), 3.33–3.37 (m, 1H), 6.12 (d, *J* = 3.8 Hz, 1H), 6.91 (d, *J* = 3.8 Hz, 1H), 6.97 (t, *J* = 5.4 Hz, 1H), 7.35 (d, *J* = 8.4 Hz, 2H), 7.38 (d, *J* = 8.4 Hz, 2H); ¹³C NMR (DMSO-*d*₆) δ 13.4, 13.5, 19.2, 30.6, 39.9, 68.5, 110.6, 127.2, 128.2, 131.9, 140.2, 154.6, 160.2, 169.1. Anal. Calcd for C₁₆H₁₉Cl₂N₃OS: C, 51.62; H, 5.14; N, 11.29. Found: C, 51.51; H, 5.17; N, 11.40.

[4-Chloro-6-(methylamino)-2-(methylsulfanyl)pyrimidin-5-yl](4-methoxyphenyl)methanol (3f): a white solid; mp 191–193 °C (hexane/THF); IR (KBr) 3420, 1575 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 2.42 (s, 3H), 2.82 (d, *J* = 4.6 Hz, 3H), 3.71 (s, 3H), 6.07 (d, *J* = 3.8 Hz, 1H), 6.68 (d, *J* = 3.8 Hz, 1H), 6.87 (d, *J* = 8.4 Hz, 2H), 7.20 (q, *J* = 4.6 Hz, 1H), 7.27 (d, *J* = 8.4 Hz, 2H); ¹³C NMR (DMSO-*d*₆) δ 13.4, 27.9, 55.1, 69.0, 111.3, 113.7, 126.7, 133.2, 154.2, 158.5, 160.8, 168.7. HR-MS (EI). Calcd for C₁₄H₁₆ClN₃O₂S (M): 325.0652. Found: *m/z* 325.0643.

{4-Chloro-2-(methylsulfanyl)-6-[(2-phenylethyl)amino]pyrimidin-5-yl}(4-methoxyphenyl)methanol (3g): a white solid; mp 135–137 °C (hexane/CH₂Cl₂); IR (KBr) 3361, 3234, 1571 cm⁻¹; ¹H NMR (CDCl₃) δ 2.51 (s, 3H), 2.78 (t, *J* = 7.4 Hz, 2H), 3.58–3.72 (m, 2H), 3.79 (s, 3H), 6.28 (s, 1H), 6.63 (t, *J* = 5.2 Hz, 1H), 6.81 (d, *J* = 9.2 Hz, 2H), 7.06 (dd, *J* = 6.9, 1.7 Hz, 2H), 7.18–7.26 (m, 6H); ¹³C NMR (CDCl₃) δ 14.1, 35.3, 42.4, 55.3, 70.6, 109.8, 113.8, 126.4, 126.9, 128.5, 128.7, 131.5, 138.8, 155.8, 159.1, 160.5, 170.3. Anal. Calcd for C₂₁H₂₂ClN₃O₂S: C, 60.64; H, 5.33; N, 10.10. Found: C, 60.62; H, 5.36; N, 9.94.

[4-Chloro-6-(methylamino)-2-(methylsulfanyl)pyrimidin-5-yl](thiophen-3-yl)methanol (3h): a white solid; mp 168–170 °C (hexane/CH₂Cl₂); IR (KBr) 3339, 3120, 1560 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 2.42 (s, 3H), 2.85 (d, *J* = 5.4 Hz, 3H), 6.14 (d, *J* = 3.8 Hz, 1H), 6.69 (d, *J* = 3.8 Hz, 1H), 7.01 (dd, *J* = 5.4, 1.5 Hz, 1H), 7.26 (q, *J* = 5.4 Hz, 1H), 7.41 (dd, *J* = 3.1, 1.5 Hz, 1H), 7.46 (dd, *J* = 5.4, 3.1 Hz, 1H); ¹³C NMR (DMSO-*d*₆) δ 13.4, 27.9, 67.1, 110.7, 121.7, 125.8, 126.5, 142.4, 153.8, 160.6, 168.7. HR-MS (EI). Calcd for C₁₁H₁₂ClN₃OS₂ (M): 301.0110. Found: *m/z* 301.0095.

1-[4-Chloro-6-(methylamino)-2-(methylsulfanyl)pyrimidin-5-yl]propan-1-ol (3i): a white solid; mp 171–173 °C (hexane/CH₂Cl₂); IR (KBr) 3357, 3267, 1568 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 0.86 (t, *J* = 7.6 Hz, 3H), 1.54–1.63 (m, 1H), 1.68–1.77 (m, 1H), 2.42 (s, 3H), 2.88 (d, *J* = 4.6 Hz, 3H), 4.87 (t, *J* = 8.4 Hz, 1H), 6.04 (br s, 1H), 7.39 (br s, 1H); ¹³C NMR (DMSO-*d*₆) δ 10.4, 13.4, 27.1, 27.8, 70.0, 111.1, 153.7, 161.0, 168.2. Anal. Calcd for C₉H₁₄ClN₃OS: C, 43.63; H, 5.70; N, 16.96. Found: C, 43.62; H, 5.68; N, 16.63.

1-[4-Chloro-6-(methylamino)-2-(methylsulfanyl)pyrimidin-5-yl]-2-methylpropan-1-ol (3j): a white solid; mp 202–204 °C (CH₂Cl₂); IR (KBr) 3326, 3209, 1562 cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 0.73 (d, *J* = 6.3 Hz, 3H), 0.98 (d, *J* = 6.3 Hz, 3H), 2.00–2.04 (m, 1H), 2.42 (s, 3H), 2.87 (d, *J* = 4.6 Hz, 3H), 4.60 (dd, *J* = 8.0, 3.4 Hz, 1H), 6.03 (d, *J* = 3.4 Hz, 1H), 7.29 (q, *J* = 4.6 Hz, 1H); ¹³C NMR (DMSO-*d*₆) δ 13.4, 19.1, 19.2, 27.9, 31.7, 73.9, 110.7, 154.5, 161.2, 168.2. Anal. Calcd for C₁₀H₁₆ClN₃OS: C, 45.88; H, 6.16; N, 16.05. Found: C, 45.74; H, 6.05; N, 15.85.

Typical Procedure for the Preparation of 1,4-dihydro-2H-pyrimido[4,5-*d*][1,3]oxazin-2-ones (4).
5-Chloro-1-methyl-7-(methylsulfanyl)-4-phenyl-1,4-dihydro-2H-pyrimido[4,5-*d*][1,3]oxazin-2-one (4a). To a stirred suspension of NaH (60% in mineral oil; 25 mg, 0.63 mmol) in THF (3 mL) at 0 °C was added a solution of **3a** (0.19 g, 0.63 mmol) in THF (2 mL) dropwise. After evolution of H₂ gas had ceased, ClCO₂Et (68 mg, 0.63 mmol) was added, and stirring was continued for 10 min at the same temperature. Saturated aqueous NH₄Cl (15 mL) was added and the mixture was extracted with AcOEt (3 × 10 mL). The combined extracts were washed with brine (10 mL), dried (Na₂SO₄), and concentrated by evaporation. The residue was purified by column chromatography on silica gel (AcOEt/hexane 1:6) to give **4a** (0.15 g, 75%); a white solid; mp 102–104 °C (hexane/CH₂Cl₂); IR (KBr) 1740, 1542 cm⁻¹; ¹H NMR (CDCl₃) δ 2.59 (s, 3H), 3.45 (s, 3H), 6.46 (s, 1H), 7.27 (dd, *J* = 6.9, 1.7 Hz, 2H), 7.38–7.39 (m, 3H); ¹³C NMR (CDCl₃) δ 14.4, 30.1, 75.9, 106.9, 126.6, 129.2, 129.8, 135.9, 150.4, 156.1, 156.3, 173.5. HR-MS (EI). Calcd for C₁₄H₁₂ClN₃O₂S (M): 321.0339. Found: *m/z* 321.0330. Anal. Calcd for C₁₄H₁₂ClN₃O₂S: C, 52.26; H, 3.76; N, 13.06. Found: C, 52.28; H, 3.90; N, 12.92.

5-Chloro-1-ethyl-7-(methylsulfanyl)-4-phenyl-1,4-dihydro-2H-pyrimido[4,5-*d*][1,3]oxazin-2-one (4b): a white solid; mp 113–115 °C (hexane/CH₂Cl₂); IR (KBr) 1734, 1546 cm⁻¹; ¹H NMR (CDCl₃) δ 1.26

(t, $J = 6.9$ Hz, 3H), 2.59 (s, 3H), 4.06–4.14 (m, 2H), 6.42 (s, 1H), 7.38 (s, 5H); ^{13}C NMR (CDCl_3) δ 12.7, 14.4, 38.7, 76.0, 106.9, 126.7, 129.2, 129.8, 136.0, 149.8, 155.9, 156.2, 173.4. HR-MS (EI). Calcd for $\text{C}_{15}\text{H}_{14}\text{ClN}_3\text{O}_2\text{S}$ (M): 335.0495. Found: m/z 335.0491. Anal. Calcd for $\text{C}_{15}\text{H}_{14}\text{ClN}_3\text{O}_2\text{S}$: C, 53.65; H, 4.20; N, 12.51. Found: C, 53.47; H, 4.31; N, 12.55.

5-Chloro-7-(methylsulfanyl)-4-phenyl-1-(phenylmethyl)-1,4-dihydro-2H-pyrimido[4,5-*d*][1,3]oxazin-2-one (4c): a white solid; mp 136–138 °C (hexane/ CH_2Cl_2); IR (KBr) 1742, 1542 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.53 (s, 3H), 5.25 (d, $J = 14.9$ Hz, 1H), 5.31 (d, $J = 14.9$ Hz, 1H), 6.44 (s, 1H), 7.17–7.47 (m, 10H); ^{13}C NMR (CDCl_3) δ 14.4, 46.0, 76.1, 107.4, 126.8, 127.7, 128.0, 128.4, 129.1, 129.7, 135.8, 136.0, 150.3, 155.8, 156.2, 173.3. HR-MS (ESI). Calcd for $\text{C}_{20}\text{H}_{17}\text{ClN}_3\text{O}_2\text{S}$ (M+H): 398.0730. Found: m/z 398.0719. Anal. Calcd for $\text{C}_{20}\text{H}_{16}\text{ClN}_3\text{O}_2\text{S}$: C, 60.38; H, 4.05; N, 10.56. Found: C, 60.15; H, 4.11; N, 10.58.

5-Chloro-4-(4-chlorophenyl)-1-methyl-7-(methylsulfanyl)-1,4-dihydro-2H-pyrimido[4,5-*d*][1,3]oxazin-2-one (4d): a pale-yellow solid; mp 157–159 °C (AcOEt); IR (KBr) 1736, 1544 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.59 (s, 3H), 3.44 (s, 3H), 6.43 (s, 1H), 7.21 (d, $J = 8.6$ Hz, 2H), 7.36 (d, $J = 8.6$ Hz, 2H); ^{13}C NMR (CDCl_3) δ 14.4, 30.2, 75.2, 106.3, 127.3, 128.0, 129.1, 129.4, 134.4, 156.1, 156.2, 173.8. HR-MS (ESI). Calcd for $\text{C}_{14}\text{H}_{12}\text{Cl}_2\text{N}_3\text{O}_2\text{S}$ (M+H): 356.0027. Found: m/z 356.0014. Anal. Calcd for $\text{C}_{14}\text{H}_{11}\text{Cl}_2\text{N}_3\text{O}_2\text{S}$: C, 47.20; H, 3.11; N, 11.80. Found: C, 47.30; H, 3.46; N, 11.66.

1-Butyl-5-chloro-4-(4-chlorophenyl)-7-(methylsulfanyl)-1,4-dihydro-2H-pyrimido[4,5-*d*][1,3]oxazin-2-one (4e): a white solid; mp 89–91 °C (hexane/ CH_2Cl_2); IR (KBr) 1734, 1578 cm^{-1} ; ^1H NMR (CDCl_3) δ 0.90 (t, $J = 7.4$ Hz, 3H), 1.23–1.28 (m, 2H), 1.57–1.63 (m, 2H), 2.58 (s, 3H), 3.97–4.02 (m, 1H), 4.07–4.13 (m, 1H), 6.40 (s, 1H), 7.20 (d, $J = 8.0$ Hz, 2H), 7.36 (d, $J = 8.0$ Hz, 2H); ^{13}C NMR (CDCl_3) δ 13.7, 14.4, 19.8, 29.4, 43.1, 75.1, 106.5, 128.0, 129.4, 134.5, 135.8, 149.8, 156.0, 156.2, 173.7. HR-MS (ESI). Calcd for $\text{C}_{17}\text{H}_{18}\text{Cl}_2\text{N}_3\text{O}_2\text{S}$ (M+H): 398.0497. Found: m/z 398.0492. Anal. Calcd for $\text{C}_{17}\text{H}_{17}\text{Cl}_2\text{N}_3\text{O}_2\text{S}$: C, 51.26; H, 4.30; N, 10.55. Found: C, 51.34; H, 4.36; N, 10.59.

5-Chloro-4-(4-methoxyphenyl)-1-methyl-7-(methylsulfanyl)-1,4-dihydro-2H-pyrimido[4,5-*d*][1,3]-oxazin-2-one (4f): a white solid; mp 128–130 °C (hexane/ CH_2Cl_2); IR (KBr) 1738, 1578 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.59 (s, 3H), 3.45 (s, 3H), 3.80 (s, 3H), 6.40 (s, 1H), 6.88 (d, $J = 8.6$ Hz, 2H), 7.17 (d, $J = 8.6$ Hz, 2H); ^{13}C NMR (CDCl_3) δ 14.4, 30.1, 55.3, 75.9, 107.0, 114.5, 127.9, 128.3, 150.5, 156.1, 156.3, 160.6, 173.3. HR-MS (ESI). Calcd for $\text{C}_{15}\text{H}_{15}\text{ClN}_3\text{O}_3\text{S}$ (M+H): 352.0522. Found: m/z 352.0526. Anal. Calcd for $\text{C}_{15}\text{H}_{14}\text{ClN}_3\text{O}_3\text{S}$: C, 51.21; H, 4.01; N, 11.94. Found: C, 51.21; H, 4.02; N, 11.93.

5-Chloro-4-(4-methoxyphenyl)-7-(methylsulfanyl)-1-(2-phenylethyl)-1,4-dihydro-2H-pyrimido[4,5-*d*][1,3]oxazin-2-one (4g): a pale-yellow solid; mp 130–132 °C (hexane/ CH_2Cl_2); IR (KBr) 1740, 1611, 1576 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.61 (s, 3H), 2.95–3.00 (m, 2H), 3.80 (s, 3H), 4.22–4.28 (m, 1H),

4.35–4.40 (m, 1H), 6.37 (s, 1H), 6.85 (d, $J = 8.6$ Hz, 2H), 7.10 (d, $J = 8.6$ Hz, 2H), 7.19–7.22 (m, 3H), 7.26 (t, $J = 7.4$ Hz, 2H); ^{13}C NMR (CDCl_3) δ 14.4, 33.7, 44.3, 55.3, 76.0, 107.0, 114.5, 126.6, 127.9, 128.3, 128.5, 128.8, 137.8, 149.9, 155.9, 156.2, 160.6, 173.2. HR-MS (ESI). Calcd for $\text{C}_{22}\text{H}_{21}\text{ClN}_3\text{O}_3\text{S}$ (M+H): 442.0992. Found: m/z 442.0984. Anal. Calcd for $\text{C}_{22}\text{H}_{20}\text{ClN}_3\text{O}_3\text{S}$: C, 59.79; H, 4.56; N, 9.51. Found: C, 59.81; H, 4.50; N, 9.39.

5-Chloro-1-methyl-7-(methylsulfonyl)-4-(thiophen-3-yl)-1,4-dihydro-2H-pyrimido[4,5-*d*][1,3]oxazin-2-one (4h): a white solid; mp 119–121 °C (hexane/ CH_2Cl_2); IR (KBr) 1733, 1582 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.59 (s, 3H), 3.45 (s, 3H), 6.50 (s, 1H), 7.07 (d, $J = 5.2$ Hz, 1H), 7.17 (br s, 1H), 7.36 (dd, $J = 5.2, 1.7$ Hz, 1H); ^{13}C NMR (CDCl_3) δ 14.4, 30.1, 72.2, 107.3, 124.0, 125.5, 127.8, 137.1, 150.5, 155.6, 156.2, 173.5. HR-MS (ESI). Calcd for $\text{C}_{12}\text{H}_{11}\text{ClN}_3\text{O}_2\text{S}_2$ (M+H): 327.9981. Found: m/z 327.9979. Anal. Calcd for $\text{C}_{12}\text{H}_{10}\text{ClN}_3\text{O}_2\text{S}_2$: C, 43.97; H, 3.08; N, 12.82. Found: C, 44.10; H, 3.22; N, 12.78.

5-Chloro-4-ethyl-1-methyl-7-(methylsulfonyl)-1,4-dihydro-2H-pyrimido[4,5-*d*][1,3]oxazin-2-one (4i): a pale-yellow solid; mp 118–120 °C (hexane/ CH_2Cl_2); IR (KBr) 1729, 1548 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.08 (t, $J = 7.4$ Hz, 3H), 1.89 (quint, $J = 7.4$ Hz, 2H), 2.57 (s, 3H), 3.46 (s, 3H), 5.38 (t, $J = 7.4$ Hz, 1H); ^{13}C NMR (CDCl_3) δ 9.0, 14.3, 28.2, 30.0, 76.6, 107.7, 150.7, 155.0, 156.0, 172.8. HR-MS (EI). Calcd for $\text{C}_{10}\text{H}_{12}\text{ClN}_3\text{O}_2\text{S}$ (M): 273.0339. Found: m/z 273.0352. Anal. Calcd for $\text{C}_{10}\text{H}_{12}\text{ClN}_3\text{O}_2\text{S}$: C, 43.88; H, 4.42; N, 15.35. Found: C, 43.85; H, 4.43; N, 15.06.

5-Chloro-1-methyl-4-(1-methylethyl)-7-(methylsulfonyl)-1,4-dihydro-2H-pyrimido[4,5-*d*][1,3]oxazin-2-one (4j): a white solid; mp 95–97 °C (hexane/ CH_2Cl_2); IR (KBr) 1747, 1543 cm^{-1} ; ^1H NMR (CDCl_3) δ 0.98 (d, $J = 6.9$ Hz, 3H), 1.10 (d, $J = 6.9$ Hz, 3H), 2.13–2.19 (m, 1H), 2.57 (s, 3H), 3.45 (s, 3H), 5.24 (d, $J = 5.7$ Hz, 1H); ^{13}C NMR (CDCl_3) δ 14.3, 16.2, 18.6, 29.9, 34.0, 80.1, 106.8, 150.9, 155.7, 156.3, 172.8. HR-MS (EI). Calcd for $\text{C}_{11}\text{H}_{14}\text{ClN}_3\text{O}_2\text{S}$ (M): 287.0495. Found: m/z 287.0486. Anal. Calcd for $\text{C}_{11}\text{H}_{14}\text{ClN}_3\text{O}_2\text{S}$: C, 45.91; H, 4.90; N, 14.60. Found: C, 45.89; H, 5.02; N, 14.48.

ACKNOWLEDGEMENTS

We would like to thank Mrs. Miyuki Tanmatsu of this university for recording mass spectra and performing combustion analyses.

REFERENCES AND NOTES

- (a) H. G. Selnick and I. M. Bell, *PCT Int. Appl.*, 2009, WO 2009105348 (*Chem. Abstr.*, 2009, **151**, 305224); (b) A. G. Cole, P. A. Jokiel, M.-R. Brescia, L. Qin, and I. Henderson, *PCT Int. Appl.*, 2009, WO 2009158309 (*Chem. Abstr.*, 2009, **152**, 119661); (c) J. R. Allen, A. Amegadzie, K. L. Andrews, J. Brown, N. Chen, E. H. Harrington, Q. Liu, T. T. Nguyen, A. J. Pickrell, W. Qian, S. Rumfelt, R.

- M. Rzasa, C. C. Yuan, and W. Zhong, *U.S. Pat. Appl. Publ.*, 2013, US 20130225552 (*Chem. Abstr.*, 2013, **159**, 426484); (d) S. Ashwell, A.-M. Campbell, J. A. Caravella, R. B. Diebold, A. Ericsson, G. Gustafson, D. R. Lancia, J. Lin, W. Lu, and Z. Wang, *PCT Int. Appl.*, 2016, WO 2016171755 (*Chem. Abstr.*, 2016, **165**, 533319); (e) R. A. Bauer, S. L. Boulet, T. P. Burkholder, M. S. Carballares, J. R. Gillig, R. Gilmour, W. A. L. A. W. Lumeras, and Z. Wu, *PCT Int. Appl.*, 2017, WO 2017019429 (*Chem. Abstr.*, 2017, **166**, 217888); (f) H. Li, Y. Xu, H. Xie, Y. Hao, Z. Chen, D. Sun, J. Lv, Y. Xu, Y. Tong, H. Chen, Z. Zhao, and J. Ding, *PCT Int. Appl.*, 2017, WO 2017144025 (*Chem. Abstr.*, 2017, **167**, 329642); (g) Y. Hao, J. Lyu, R. Qu, D. Sun, Z. Zhao, Z. Chen, J. Ding, H. Xie, Y. Xu, and H. Li, *Sci. Rep.*, 2017, **7**, 3830.
2. (a) K. Kobayashi, K. Nakazawa, S. Yuba, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2015, **90**, 216; (b) K. Kobayashi, R. Ono, S. Yuba, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2015, **91**, 1177; (c) K. Kobayashi, R. Ono, K. Ishitobi, Y. Chikazawa, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2016, **92**, 260; (d) K. Kobayashi, D. Fujiwara, Y. Shigemura, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2017, **94**, 140; (e) K. Kobayashi, I. Nozawa, T. Ueyama, H. Utsumi, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2017, **94**, 1427; (f) K. Kobayashi, T. Nogi, Y. Tsunomori, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2017, **94**, 2087; (g) K. Kobayashi, R. Ono, K. Ishitobi, I. Murayama, H. Hiyoshi, and K. Umezu, *Heterocycles*, 2018, **96**, 287. See also refs. cited therein.